SCHEMBL30748772

SCHEMBL30748772

OCc1ncc(C2CCCO2)c(Nc2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.44
POLB P06746 3/20 0.43
NPC1 O15118 2/20 0.43
HPGD P15428 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
SYK P43405 2/20 0.39
HTT P42858 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
GCK P35557 1/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748873 0.85 PDE10A (0.46) PDE10APOLBNPC1HPGDRAB9A
SCHEMBL30748966 0.82 PDE10A (0.44) PDE10APOLBNPC1HPGDRAB9A
SCHEMBL30748911 0.82 PDE10A (0.44) PDE10APOLBNPC1HPGDRAB9A
SCHEMBL30748748 0.74 MAP2K1 (0.56) KDRPIN1MAP2K1
SCHEMBL30749029 0.73 FLT3 (0.47) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL30748898 0.71 EGFR (0.41) TP53SYKSMN1; SMN2MAPTKDR
SCHEMBL30749018 0.70 SYK (0.40) NPC1RAB9ASYKKMT2ASMN1; SMN2
SCHEMBL30749039 0.66 HTR2C (0.49) MAPK1KDRTEKPIN1TTBK1
SCHEMBL30748744 0.66 ERBB2 (0.50) NPC1RAB9ASYKKMT2AMEN1
SCHEMBL2488310 0.65 PDE10A (0.67) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PDE10A 1621/4885POLB 683/4885NPC1 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.